The STRIDER trial: one step forward, one step back

Affiliations

¹ Department of Obstetrics and Gynaecology, University of Cambridge, Box 223 The Rosie Hospital, Cambridge CB2 0SW, UK; National Institute of Health Research Cambridge Comprehensive Biomedical Research Centre, Cambridge, UK. Electronic address: gcss2@cam.ac.uk.

Free article

Comment

Gordon C S Smith. Lancet Child Adolesc Health. 2018 Feb.

Free article

. 2018 Feb;2(2):80-81.

doi: 10.1016/S2352-4642(17)30176-1. Epub 2017 Dec 7.

¹ Department of Obstetrics and Gynaecology, University of Cambridge, Box 223 The Rosie Hospital, Cambridge CB2 0SW, UK; National Institute of Health Research Cambridge Comprehensive Biomedical Research Centre, Cambridge, UK. Electronic address: gcss2@cam.ac.uk.

No abstract available

Comment on

Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial.
Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorghiou AT, Alfirevic Z; STRIDER group. Sharp A, et al. Lancet Child Adolesc Health. 2018 Feb;2(2):93-102. doi: 10.1016/S2352-4642(17)30173-6. Epub 2017 Dec 7. Lancet Child Adolesc Health. 2018. PMID: 30169244 Clinical Trial.